Published in:
01-11-2017 | Basic Science
Inhibition of TLR4 alleviates the inflammation and apoptosis of retinal ganglion cells in high glucose
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 11/2017
Login to get accessAbstract
Purpose
To investigate the expression profiles of Toll-like receptor 4 (TLR4), the effect of TLR4 on inflammation, and apoptosis of retinal ganglion cells (RGCs) cultured in high glucose and the underlying mechanism.
Methods
A high-glucose model was established in RGCs isolated from Sprague-Dawley (SD) rats (2–3 days old) and identified with Brn3a. Primary cultured RGCs were divided into control (0 mM), HG1 (10 mM glucose), HG2 (20 mM glucose), HG3 (30 mM glucose), HG (20 mM glucose) + TAK-242 (1.0 μM), and HG (20 mM glucose) + vehicle (1% DMSO) groups. The expression levels of TLR4, its downstream signalling molecules, and pro-inflammatory cytokines were measured by real-time PCR, Western blot or ELISA at 24 h and 48 h. The apoptosis rate of RGCs was measured by flow cytometry.
Results
The mRNA and protein expression levels of TLR4 were increased in high-glucose groups (10 mM, 20 mM, 30 mM). Consistent with these findings, four TLR4 downstream signalling molecules (MyD88, NF-κB, TRAF6, NLRP3) and pro-inflammatory cytokines (IL-1β, IL-18) were upregulated in the three high-glucose groups. Apoptosis of RGCs was clearly increased in the high-glucose group. The administration of TAK-242, an antagonist of TLR4, inhibited inflammation and apoptosis of RGCs in the high-glucose group.
Conclusion
Our results demonstrated that TLR4 plays a critical role in the inflammation and apoptosis of RGCs induced by high glucose. TLR4 might become a novel potential pharmacological target for preventing the progression of DR.